Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
239
-
Total 13F shares, excl. options
-
50.7M
-
Shares change
-
+17.8K
-
Total reported value, excl. options
-
$3.58B
-
Value change
-
+$7.33M
-
Put/Call ratio
-
1.26
-
Number of buys
-
114
-
Number of sells
-
-133
-
Price
-
$70.59
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2021
301 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q3 2021.
HAEMONETICS CORP - Common Stock (HAE) has 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.7M shares
.
Largest 10 shareholders include BlackRock Inc. (6.99M shares), VANGUARD GROUP INC (4.89M shares), WELLINGTON MANAGEMENT GROUP LLP (4.24M shares), Neuberger Berman Group LLC (3.83M shares), STATE STREET CORP (1.66M shares), FRANKLIN RESOURCES INC (1.48M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1.36M shares), JANUS HENDERSON GROUP PLC (1.2M shares), LGT CAPITAL PARTNERS LTD. (1.18M shares), and Capital Research Global Investors (1.13M shares).
This table shows the top 239 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.